HF
KTTAW icon

HRT Financial’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

HRT Financial’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,483
Closed -$4K – 3490
2021
Q4 		$4K Buy
+12,483
New +$6.15K ﹤0.01% 3058

Other funds holding KTTAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HRT Financial's KTTAW Position: Q1 2022 in Review

HRT Financial sold out of Pasithea Therapeutics Warrants (KTTAW) in Q1 2022, closing a stake of 12,483 shares — an estimated $4K sold.

HRT Financial first reported a position in KTTAW in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 4 funds tracked by Wall St. Rank hold KTTAW as of Q1 2022.

  • HRT Financial reported no remaining Pasithea Therapeutics Warrants position as of Q1 2022 after selling out during the quarter.
  • HRT Financial sold 12,483 Pasithea Therapeutics Warrants shares in Q1 2022, an estimated $4K.
  • HRT Financial first reported a position in Pasithea Therapeutics Warrants in Q4 2021 and held it in 1 quarter.
  • HRT Financial's Pasithea Therapeutics Warrants position peaked at $4K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.